ATHA 241115 7.50C (ATHA241115C7500) Stock Options, News & Quotes

US OptionsDetailed Quotes

ATHA241115C7500

Watchlist

0.00
0.000.00%

15min DelayClose Oct 30 09:30 ET

0.00High0.00Low

Intraday

5D
Daily

No Data

News

Athira Pharma to Present Results From Phase 2/3 LIFT-AD Trial
TipRanksOct 22 07:21 ET
Express News | Athira Pharma Inc - Files for Mixed Shelf Offering of up to $300 Mln - SEC Filing
ReutersOct 21 06:25 ET
Express News | Athira Pharma: Co Has Until April 14, 2025, to Regain Compliance
ReutersOct 18 16:06 ET
Express News | Athira Pharma: Receives Nasdaq Non-Compliance Notice
ReutersOct 18 16:04 ET
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
Seeking AlphaOct 4 14:02 ET
Robinhood To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Thursday
BenzingaSep 19 08:29 ET

Comments

skinnydippi

Oct 22 13:42

$Athira (ATHA.US)$ 👀

$Athira (ATHA.US)$
that's alot of extra cash

Jaguar8

Sep 17 08:20

NEWS

$Athira (ATHA.US)$
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases
Athira Pharma (NASDAQ: ATHA) announced a strategic shift to focus on advancing ATH-1105, an oral, next-generation small molecule positive modulator of the HGF system, for treating neurodegenerative diseases like ALS and Alzheimer's. This decision follows the topline data readout from the Phase 2/3 LIFT-AD trial of fosgonimeton. The company is implementing cost containment meas...

FattyChick

Sep 5 08:12

$Athira (ATHA.US)$ Entry 0.39